Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
130 900
258 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Sam Chun Dang Pharm Co Ltd
Sam Chun Dang Pharm Co Ltd is a quintessential tale of innovation and resilience in the ever-evolving pharmaceutical landscape. Founded in 1943, this South Korean company has steadily crafted its way into becoming a significant player in the generic drug market. Initially focusing on traditional herbal remedies, the company astutely shifted its focus towards the production of generic drugs, capitalizing on the increasing demand for cost-effective alternatives to branded medications. Sam Chun Dang's business model pivots on manufacturing and distributing a wide range of pharmaceutical products, including prescription drugs, over-the-counter medicines, and active pharmaceutical ingredients, catering to both domestic and international markets.
The company thrives by meticulously investing in research and development, ensuring a robust pipeline of new generics ready for market entry as patents on branded drugs expire. By emphasizing quality and affordability, Sam Chun Dang Pharm Co Ltd leverages its state-of-the-art manufacturing facilities, accredited by international standards, to maintain a competitive edge. Their profitability stems from not only their comprehensive product lineup but also strategic partnerships and collaborations that enhance their market penetration. Despite operating within a highly competitive and regulated industry, Sam Chun Dang’s commitment to consistent quality and innovation helps them sustain revenue growth and solidify their position as a reputable pharmaceutical provider.
Sam Chun Dang Pharm Co Ltd is a quintessential tale of innovation and resilience in the ever-evolving pharmaceutical landscape. Founded in 1943, this South Korean company has steadily crafted its way into becoming a significant player in the generic drug market. Initially focusing on traditional herbal remedies, the company astutely shifted its focus towards the production of generic drugs, capitalizing on the increasing demand for cost-effective alternatives to branded medications. Sam Chun Dang's business model pivots on manufacturing and distributing a wide range of pharmaceutical products, including prescription drugs, over-the-counter medicines, and active pharmaceutical ingredients, catering to both domestic and international markets.
The company thrives by meticulously investing in research and development, ensuring a robust pipeline of new generics ready for market entry as patents on branded drugs expire. By emphasizing quality and affordability, Sam Chun Dang Pharm Co Ltd leverages its state-of-the-art manufacturing facilities, accredited by international standards, to maintain a competitive edge. Their profitability stems from not only their comprehensive product lineup but also strategic partnerships and collaborations that enhance their market penetration. Despite operating within a highly competitive and regulated industry, Sam Chun Dang’s commitment to consistent quality and innovation helps them sustain revenue growth and solidify their position as a reputable pharmaceutical provider.
